US 11,964,015 B2
Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
Barbara Leuchs, Heidelberg (DE); Antonio Marchini, Heidelberg (DE); Jean Rommelaere, Heidelberg (DE); Assia Angelova, Heidelberg (DE); Dirk Jager, Mainz-Kostheim (DE); Wolfgang Wick, Heidelberg (DE); and Michael Dahm, Munich (DE)
Assigned to DEUTSCHES KREBSFORSCHUNGSZENTRUM, Heidelberg (DE); and RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG, Heidelberg (DE)
Filed by DEUTSCHES KREBSFORSCHUNGSZENTRUM, Heidelberg (DE); and RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG, Heidelberg (DE)
Filed on Apr. 9, 2021, as Appl. No. 17/226,199.
Application 17/226,199 is a division of application No. 16/148,257, filed on Oct. 1, 2018, granted, now 11,027,013.
Application 16/148,257 is a continuation in part of application No. PCT/EP2017/056886, filed on Mar. 22, 2017.
Claims priority of application No. 16163555 (EP), filed on Apr. 1, 2016; and application No. 16020193 (EP), filed on May 27, 2016.
Prior Publication US 2021/0228714 A1, Jul. 29, 2021
Int. Cl. A61K 35/768 (2015.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/39541 (2013.01) [A61K 35/768 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C12N 2750/14332 (2013.01)] 6 Claims
 
1. A method of treating cancer comprising administering a pharmaceutical combination containing (a) parvovirus H-1 and (b) an anti-PD1 antibody or an anti-PD-L1 antibody.